David L Becton, MD

Research Program: Cancer Therapeutics Faculty Rank: Professor Campus: Arkansas Children's Hospital College: College of Medicine Department: Peds Hematology

Contact Information

• Email Address: BECTONDAVIDL@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “ANBL2131, A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma” (NCT06172296)
• “ACCL1931 A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy” (NCT05602194)
• “AHOD2131, A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphom” (NCT05675410)
• “ACNS2021, A Phase 2 Trial of Chemotherapy followed by Response Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor” (NCT04684368)
• “BCC015 - Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma” (NCT02154490)
• “A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged 1-30 Years with First Relapse” (NCT04546399)
• “AALL1732 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-Lly” (NCT03959085)
• “ARST2032 Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma” (NCT05304585)
• “AGCT1532 A Ramdomized Phase 3 Trial of Accelerated vs. Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors” (NCT02582697)
• “AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma” (NCT05235165)

Recent Publications

• Gill PS, Yu FB, Porter-Gill PA, [et al., including Becton DL]. Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital. Journal of personalized medicine. 2021 11(5). PMID: 34064668. PMCID: PMC8150685.
• Mack JM, Pierce CD, Richter GT, [et al., including Becton D]. Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography. Pediatric blood & cancer. 2020:e28824. PMID: 33211399.